Literature DB >> 28554253

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Matthew J Pianko1, Samuel A Funt1, David B Page2, Deepika Cattry1, Emma C Scott3, Stephen M Ansell4, Ivan M Borrello5, Martin Gutierrez6, Nikoletta Lendvai1, Hani Hassoun1, C Ola Landgren1, Alexander M Lesokhin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28554253      PMCID： PMC5645787          DOI： 10.1080/10428194.2017.1320713

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  11 in total

1.  Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors:  Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal:  N Engl J Med       Date:  2015-06-02       Impact factor: 91.245

2.  T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Authors:  David J Chung; Katherine B Pronschinske; Justin A Shyer; Sneh Sharma; Samantha Leung; Shane A Curran; Alexander M Lesokhin; Sean M Devlin; Sergio A Giralt; James W Young
Journal:  Cancer Immunol Res       Date:  2015-10-13       Impact factor: 11.151

3.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Authors:  Jeffrey A Zonder; Ann F Mohrbacher; Seema Singhal; Frits van Rhee; William I Bensinger; Han Ding; John Fry; Daniel E H Afar; Anil K Singhal
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

Review 4.  Allogeneic hematopoietic cell transplantation for multiple myeloma.

Authors:  W I Bensinger; D Maloney; R Storb
Journal:  Semin Hematol       Date:  2001-07       Impact factor: 3.851

5.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 8.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

9.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Authors:  Pieter Sonneveld; Hervé Avet-Loiseau; Sagar Lonial; Saad Usmani; David Siegel; Kenneth C Anderson; Wee-Joo Chng; Philippe Moreau; Michel Attal; Robert A Kyle; Jo Caers; Jens Hillengass; Jesús San Miguel; Niels W C J van de Donk; Hermann Einsele; Joan Bladé; Brian G M Durie; Hartmut Goldschmidt; María-Victoria Mateos; Antonio Palumbo; Robert Orlowski
Journal:  Blood       Date:  2016-03-21       Impact factor: 22.113

10.  Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Rachael Sexton; Rituparna Das; Kavita M Dhodapkar; Lin Zhang; Ranjini Sundaram; Sonal Soni; John J Crowley; Robert Z Orlowski; Bart Barlogie
Journal:  Blood       Date:  2015-10-14       Impact factor: 25.476
View more
  4 in total

Review 1.  Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

Authors:  Matthew J Pianko; Alison J Moskowitz; Alexander M Lesokhin
Journal:  Clin Cancer Res       Date:  2017-09-12       Impact factor: 12.531

Review 2.  Cancer immune therapy for lymphoid malignancies: recent advances.

Authors:  Uffe Klausen; Nicolai Grønne Dahlager Jørgensen; Jacob Handlos Grauslund; Morten Orebo Holmström; Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2018-07-13       Impact factor: 9.623

Review 3.  The challenges of checkpoint inhibition in the treatment of multiple myeloma.

Authors:  Barry Paul; Shuqi Kang; Zhihong Zheng; Yubin Kang
Journal:  Cell Immunol       Date:  2018-10-13       Impact factor: 4.868

Review 4.  Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.

Authors:  Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Marta Pugliese; Eleonora Di Salvo; Elvira Ventura-Spagnolo; Caterina Musolino; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.